ArticleJournal of cardiovascular development and disease2026
A Nomogram Integrating Inflammatory Biomarkers and Echocardiographic Parameters for Predicting Left Ventricular Outflow Tract Obstruction Risk in Hypertrophic Cardiomyopathy.
Article in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveAlthough echocardiography is the gold standard for diagnosing left ventricularoutflow tract obstruction (LVOTO) in hypertrophic cardiomyopathy (HCM), relying solely on imaging is insufficient for precise risk stratification, particularly in borderline or atypical patients, and fails to capture systemic pathophysiological alterations. In recent years, novel inflammatory biomarkers derived from routine blood tests have shown sensitivity in capturing micro-inflammatory states; however, their specific roles in the obstructive phenotype of HCM remain unclear. This study aims to screen hematological and cardiac parameters associated with HCM obstruction and to construct an individualized predictive model. Therefore, this study aims to screen hematological and cardiac parameters associated with HCM obstruction and to develop and validate a nomogram for individualized prediction of current LVOTO risk in HCM patients.
methodsA total of 230 HCM patients hospitalized at The Central Hospital of Wuhan from January 2019 to December 2025 were retrospectively enrolled. Based on the left ventricular outflow tract pressure gradient (LVOTPG), they were divided into a non-obstruction group (
resultsMultivariate logistic regression analysis revealed that a history of alcohol consumption (OR = 3.68, 95% CI: 1.49-9.09), peak LVOTPG (OR = 3.96, 95% CI: 1.42-11.05), maximum ventricular wall thickness (OR = 1.02, 95% CI: 1.00-1.04), peak mitral valve E-wave velocity (OR = 1.02, 95% CI: 1.00-1.04), and neutrophil count (OR = 2.42, 95% CI: 1.13-5.21) were independent predictors of LVOTO in HCM patients. The nomogram model constructed based on these factors achieved area under the curve (AUC) values of 0.810 and 0.850 in the training and validation sets, respectively. The calibration curve demonstrated good agreement between predicted and actual probabilities, and DCA indicated that the model provided clinical net benefit within a threshold probability range of 10% to 30%.
conclusionsA nomogram integrating alcohol consumption history, peak LVOTPG, maximum ventricular wall thickness, peak mitral E-wave velocity, and neutrophil count accurately predicts LVOTO risk in HCM patients (AUC: 0.810-0.850), providing a low-cost tool for early risk stratification. External prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.